Loading
Shandong New Time Pharmaceutical is a Chinese developer in Shandong that sponsors 3 registered cancer trials of F182112 and F182112 single-agent.
Shandong New Time Pharmaceutical appears on ClinicalTrials.gov as the industry sponsor of 3 interventional cancer trials (phase 2, 2/3, 3), testing F182112, F182112 single-agent, Pomalidomide in relapsed or refractory multiple myeloma, relapsed or refractory multiple myeloma (rrmm), cancer of unknown primary site. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.
F182112 is an experimental investigational agent whose form is not stated in the registry from Shandong New Time Pharmaceutical in phase 3 trials for multiple myeloma, with its target not yet stated publicly.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.